NGM Biopharmaceuticals | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Deals

6 March 2025

Merck and Sanofi sound the alarm for ILT inhibition

Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.

Subscribe to NGM Biopharmaceuticals